Nutrineal Pd4

Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serine, the active ingredients in Nutrineal Pd4, are a mixture of essential and non‑essential amino acids presented as a sterile aqueous solution for intraperitoneal use. The formulation provides a source of protein‑derived nitrogen and calories for patients receiving peritoneal dialysis, supporting nutritional balance when oral intake is limited.

GNH USA supplies Nutrineal Pd4 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and dialysis units through regulated channels worldwide.

Nutrineal Pd4 is an intraperitoneal amino‑acid solution used to support nutrition in patients undergoing peritoneal dialysis. - Chronic kidney disease on peritoneal dialysis: provides essential amino acids to help maintain nitrogen balance and prevent protein‑energy malnutrition. - Acute kidney injury requiring peritoneal dialysis: supplies readily absorbable nutrients during the acute treatment phase. - Pediatric peritoneal dialysis: offers a tailored amino‑acid profile suitable for growing children who cannot meet needs orally. - Home peritoneal dialysis programs: enhances daily nutritional intake without additional oral supplementation.

Nutrineal Pd4 may be associated with several adverse reactions related to its intraperitoneal administration.

Common Side Effects: - Abdominal discomfort or pain during or after infusion. - Nausea or mild vomiting. - Transient hyperglycemia due to carbohydrate content of the carrier solution. - Electrolyte disturbances, particularly mild hyperkalemia. - Fluid overload if intraperitoneal volume is not carefully managed.

Serious or Rare Side Effects: - Peritonitis resulting from contamination or breach of aseptic technique. - Severe allergic reaction or anaphylaxis to any amino‑acid component. - Metabolic acidosis from excessive amino‑acid catabolism. - Significant hypernatremia or hyperosmolality. - Persistent hypotension related to rapid intraperitoneal fluid shifts.

Nutrineal Pd4 should be used with careful clinical oversight to minimise risks. - Patient selection: assess baseline protein‑energy status and renal function before initiating therapy. - Monitoring: regularly check serum electrolytes, nitrogen balance, and glucose levels during treatment. - Infection risk: maintain strict aseptic technique to avoid peritonitis. - Fluid balance: monitor intraperitoneal volume and overall fluid status to prevent overload. - Compatibility: do not mix with incompatible dialysis solutions or medications without stability data. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions with Nutrineal Pd4 should be evaluated by the prescribing clinician.

Major Interactions (Avoid): - Concurrent intraperitoneal antibiotics that significantly alter peritoneal membrane permeability, potentially affecting amino‑acid absorption. - Co‑administration with hypertonic glucose dialysis solutions, which may cause abrupt osmotic shifts and electrolyte imbalance.

Moderate Interactions (Monitor Closely): - Systemic amino‑acid or protein supplements that could increase total nitrogen load. - Loop diuretics that influence fluid and electrolyte homeostasis. - Other renal replacement therapies that provide high protein intake, requiring adjustment of the amino‑acid dose. - Medications affecting hepatic metabolism of amino acids, such as certain anticonvulsants.